IP Library Granted Patent US 8,097,410
Granted Patent B2
US 8,097,410 · App. 11/924,707 · Granted Jan 17, 2012

Methods and compositions for vitamin K epoxide reductase

Assignee: University of North Carolina at Chapel Hill
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,097,410
App. No.
11/924,707
Granted
Jan 17, 2012
Kind
B2
Abstract

The present invention provides a method of identifying a human subject having increased or decreased sensitivity to warfarin, comprising detecting in the subject the presence of a single nucleotide polymorphism in the VKOR gene, wherein the single nucleotide polymorphism is correlated with increased or decreased sensitivity to warfarin, thereby identifying the subject having increased or decreased sensitivity to warfarin.

Claims (26)

1. A method of identifying a human subject having increased sensitivity to warfarin, comprising detecting in a nucleic acid sample obtained from the subject the presence of an allele of a single nucleotide polymorphism in the VKOR gene, wherein the allele of the single nucleotide polymorphism is correlated with increased sensitivity to warfarin, thereby identifying the subject having increased sensitivity to warfarin, wherein the single nucleotide polymorphism in the VKOR gene is a G→C alteration at the position corresponding to nucleotide 2581 of SEQ ID NO:11.

2. The method of claim 1 , wherein said detecting comprises performing a nucleic acid amplification assay.

3. A method of determining a suitable dose of warfarin for a human subject, comprising detecting in a nucleic acid sample obtained from the subject the presence of an allele of a single nucleotide polymorphism in the VKOR gene, wherein the allele of the single nucleotide polymorphism is correlated with increased sensitivity to warfarin; and

identifying a suitable dose of warfarin for the subject based on said determining, wherein the allele of the single nucleotide polymorphism in the VKOR gene is a G→C alteration at the position corresponding to nucleotide 2581 of SEQ ID NO:11.

4. The method of claim 3 , further comprising administering warfarin to the subject at a dosage determined from said identifying.

5. A method of identifying a human subject having increased sensitivity to warfarin, comprising:

a) correlating the presence of an allele of a single nucleotide polymorphism in the VKOR gene with increased sensitivity to warfarin; and

b) detecting the allele of the single nucleotide polymorphism of step (a) in a nucleic acid sample obtained from the subject, thereby identifying the subject as having increased sensitivity to warfarin, wherein the allele of the single nucleotide polymorphism in the VKOR gene is a G→C alteration at the position corresponding to nucleotide 2581 of SEQ ID NO:11.

6. A method of amplifying a segment of a VKOR genomic nucleotide sequence, comprising:

a) choosing a first oligonucleotide primer from the 3′ end of a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:8;

b) choosing a second oligonucleotide primer from the 5′ end of a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:8;

c) adding said first primer and said second primer to a nucleic acid sample; and

d) amplifying a segment of the VKOR genomic nucleotide sequence defined by the first primer and the second primer, wherein the amplified segment comprises an allele of a single nucleotide polymorphism that is correlated with increased sensitivity to warfarin, wherein the allele of the single nucleotide polymorphism in the VKOR gene is a G→C alteration at the position corresponding to nucleotide 2581 of SEQ ID NO:11 and wherein said nucleic acid sample is from a subject in need of warfarin therapy.

7. A method of amplifying a segment of a VKOR genomic nucleotide sequence, comprising:

a) choosing a first oligonucleotide primer from a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:8;

b) choosing a second oligonucleotide primer from a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:8 that differs in nucleotide sequence from the first oligonucleotide primer;

c) adding said first primer and said second primer to a nucleic acid sample; and

d) amplifying a segment of the VKOR genomic nucleotide sequence defined by the first primer and the second primer, wherein the amplified segment comprises an allele of a single nucleotide polymorphism that is correlated with increased sensitivity to warfarin, wherein the allele of the single nucleotide polymorphism in the VKOR gene is a G→C alteration at the position corresponding to nucleotide 2581 of SEQ ID NO:11 and wherein said nucleic acid sample is from a subject in need of warfarin therapy.

8. The method of claim 3 , wherein said detecting comprises performing a nucleic acid amplification assay.

9. The method of claim 5 , wherein said detecting comprises performing a nucleic acid amplification assay.

10. The method of claim 1 , wherein said detecting comprises sequencing the VKOR gene at the position corresponding to nucleotide 2581 of SEQ ID NO:11.

11. The method of claim 3 , wherein said detecting comprises sequencing the VKOR gene at the position corresponding to nucleotide 2581 of SEQ ID NO:11.

12. The method of claim 5 , wherein said detecting comprises sequencing the VKOR gene at the position corresponding to 2581 of SEQ ID NO:11.

13. The method of claim 1 , wherein said detecting comprises performing a hybridization assay.

14. The method of claim 3 , wherein said detecting comprises performing a hybridization assay.

15. The method of claim 5 , wherein said detecting comprises performing a hybridization assay.

Assignments (1)
CONFIRMATORY LICENSE Recorded Nov 17, 2021
From: UNIVERSITY OF NORTH CAROLINA, CHAPEL HILL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 058166/0703 →
Continuity (3)
Continuation 10573131
Provisional Application 60505527 · Sep 23, 2003
Related Publication 20090215045A1 · Aug 27, 2009